glp-1 cardiovascular outcome trials Clinical Outcomes with Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled | Drugs Clinical application of glucagon-like peptide-1

Caution should be exercised in treating HIV-positive patients with lipodystrophy with tesamorelin if they develop glucose intolerance or diabetes, and careful consideration should be given to discontinuing tesamorelin treatment in patients who do not show a clear efficacy response as judged by the degree of reduction in visceral adipose tissue by waist circumference or CT scan measurements

Causes: Pre-renal: decreased blood flow (shock, dehydration, heart failure)

Anstey KJ, Ee N, Eramudugolla R, Jagger C, Peters R

Third, we did not perform detailed mechanistic studies to elucidate the exact pathways through which GLP-1RAs exert their cardiovascular benefits

This is not a recommendation for any medication

We want all patients to have access to reliable and effective treatment, at a lower cost, with reliable supply